Drugs / Albinterferon
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00489385 | Jun 2007 → Mar 2011 | HIV infectious disease, hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albinterferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00489385 ↗ |
| Action | Inhibit | “The results of the study will enable us to better delineate the efficacy of Alb-IFN in suppressing the hepatitis C virus in HIV/HCV coinfected subjects.” NCT00489385 ↗ |
| Modality | Protein / enzyme biologic | “Alb-IFN (interferon alpha genetically fused to human serum albumin)” NCT00489385 ↗ |
| Route | Subcutaneous | “by injection under the skin” NCT00489385 ↗ |